In male mice in this study, we found that Trpc6 deficiency improved doxorubicin-induced cardiac damage (vacuolation, fibrosis, Tnni3 and Myh7) and cardiomyopathy indicating that Trpc6 promotes cardiac damage associated with doxorubicin therapy. The gene discussed is TRPC6; the disease is cardiomyopathy.